Heme Oxygenase-1 (HO-1) Protein
Overview
Heme oxygenase-1 (HO-1, encoded by the HMOX1 gene) is a 32 kDa inducible enzyme that catalyzes the rate-limiting step in heme degradation, converting heme into biliverdin, iron (Fe²⁺), and carbon monoxide (CO). Originally characterized for its role in erythrocyte turnover and iron recycling, HO-1 has emerged as a critical cytoprotective protein in the nervous system with profound implications for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and others. [@schipper2019]
HO-1 belongs to the heme oxygenase family which includes two isoforms: the inducible HO-1 (HMOX1) and the constitutive HO-2 (HMOX2). While HO-2 is primarily expressed in the brain and testis, HO-1 is expressed at low levels under normal physiological conditions but can be dramatically induced by cellular stress, making it a central player in the cellular stress response. [@nath2019]
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Heme Oxygenase-1 (HO-1) |
| Gene Symbol | HMOX1 |
| Chromosomal Location | 22q12.3 |
| NCBI Gene ID | 3162 |
| UniProt ID | P09601 (HO1_HUMAN) |
| Molecular Weight | 32 kDa |
| Subcellular Location | Endoplasmic reticulum, mitochondria |
| Inducers | Heme, oxidative stress, cytokines, heat shock |
| Inhibitors | SnPP, ZnPP, synthetic metalloporphyrins |
</div>
Structure and Catalytic Mechanism
Protein Architecture
HO-1 is a homodimeric enzyme with each monomer consisting of:
- N-terminal transmembrane helix (residues 1-23): Anchors the protein to the endoplasmic reticulum membrane
- Heme binding pocket (residues 24-200): Contains the catalytic site where heme degradation occurs
- Proximal helix: Provides the iron ligand for heme binding
- Distal helix: Forms the substrate access channel
- C-terminal regulatory domain: Modulates enzyme activity and protein interactions
The crystal structure of HO-1 reveals a unique "sheltered" binding pocket where the heme molecule is sandwiched between two helical segments, with the catalytic Asp140 and His25 playing critical roles in the oxygenation reaction. [@alam2022]
Catalytic Reaction
The HO-1 catalyzed reaction proceeds in three steps:
Heme oxygenation: Fe²⁺-heme + O₂ + NADPH + H₂O → biliverdin + Fe²⁺ + CO + NADP⁺ + H₂O
Biliverdin reduction: Biliverdin + NADPH → bilirubin (via biliverdin reductase)
Iron release: Ferrous iron (Fe²⁺) is either sequestered by ferritin or releasedThe reaction requires NADPH-cytochrome P450 reductase (CPR) as an electron donor, making HO-1 part of the microsomal monooxygenase system. Importantly, the products of heme catabolism—biliverdin/bilirubin, CO, and ferritin-bound iron—all possess biological activities relevant to neuroprotection. [@schipper2019]
Normal Function in the Nervous System
Cytoprotective Functions
Under normal physiological conditions, HO-1 is expressed at low levels in the brain but serves critical homeostatic functions:
Antioxidant Defense: HO-1 is a key component of the Nrf2-ARE antioxidant response pathway. The Nrf2 transcription factor translocates to the nucleus upon oxidative stress and binds to the antioxidant response element (ARE) in the HMOX1 promoter, dramatically upregulating HO-1 expression. This creates a feedback loop where oxidative stress induces HO-1, and the products of heme degradation (particularly biliverdin and bilirubin) provide antioxidant protection. [@alam2022]
Anti-inflammatory Activity: HO-1 exerts potent anti-inflammatory effects through multiple mechanisms:
- Inhibition of NF-κB signaling pathway
- Suppression of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
- Promotion of anti-inflammatory M2 microglial phenotype
- Modulation of T-cell responses
The CO produced by HO-1 activity acts as a signaling molecule that inhibits inflammatory responses through modulation of MAPK pathways and inhibition of NF-κB. [@barsoum2019]
Mitochondrial Protection: HO-1 localizes to mitochondria in neurons and astrocytes, where it:
- Maintains mitochondrial membrane potential
- Preserves electron transport chain function
- Prevents mitochondrial permeability transition
- Promotes mitophagy to remove damaged mitochondria
This mitochondrial localization is particularly relevant to neurodegenerative diseases, where mitochondrial dysfunction is a central pathogenic mechanism. [@chen2023]
Iron Homeostasis: By degrading heme and promoting ferritin expression, HO-1 plays a crucial role in maintaining iron balance in the brain. The induction of HO-1 leads to increased ferritin synthesis, which sequesters potentially toxic free iron, preventing iron-catalyzed oxidative damage. This is particularly important in brain regions susceptible to iron accumulation and neurodegeneration. [@kim2023]
Cellular Distribution in the Brain
In the normal brain, HO-1 expression varies by cell type:
- Neurons: Low basal expression, rapidly inducible under stress
- Astrocytes: Constitutive expression at moderate levels, strongly induced
- Microglia: Low basal expression, highly inducible by inflammatory stimuli
- Oligodendrocytes: Limited expression, increases in demyelinating conditions
- Endothelial cells: Expresses HO-1 at blood-brain barrier interfaces
The inducible nature of HO-1 makes it a sentinel of cellular stress across all neural cell types, positioning it as a potential therapeutic target in neurodegeneration. [@schipper2000]
Role in Alzheimer's Disease
HO-1 Expression in AD Brain
Multiple studies have documented elevated HO-1 expression in [Alzheimer's disease](/diseases/alzheimers-disease) brains. Immunohistochemical analyses reveal:
- Increased HO-1 immunoreactivity in hippocampus, cortex, and amygdala
- Localization to neurons, astrocytes, and microglia surrounding amyloid plaques
- Correlation with disease severity
- Co-localization with hyperphosphorylated [tau](/proteins/tau) pathology
The upregulation of HO-1 in AD is interpreted as a compensatory neuroprotective response to oxidative stress, amyloid-beta ([Aβ](/proteins/amyloid-beta)) toxicity, and neuroinflammation. However, chronic HO-1 induction may become maladaptive, contributing to disease progression. [@song2020]
Mechanisms of HO-1 in AD Pathogenesis
Amyloid-beta Interaction: Aβ peptides directly induce HO-1 expression in neurons and glia through oxidative stress-dependent mechanisms. The HO-1 induction is part of a broader cellular stress response, but the enzyme's activity may influence Aβ metabolism:
- Biliverdin and bilirubin can inhibit Aβ aggregation in vitro
- CO signaling may modulate amyloid precursor protein (APP) processing
- HO-1-induced iron release could influence Aβ-induced oxidative stress
Oxidative Stress Modulation: AD brains exhibit severe oxidative damage to lipids, proteins, and DNA. HO-1 provides antioxidant protection through:
- Production of bilirubin, a potent lipid-soluble antioxidant
- Induction of ferritin, sequestering free iron
- CO-mediated inhibition of ROS-generating enzymes
Neuroinflammation: Chronic neuroinflammation is a hallmark of AD. HO-1 exerts anti-inflammatory effects that may be beneficial:
- Suppression of microglial activation
- Reduction in pro-inflammatory cytokine expression
- Promotion of anti-inflammatory phenotype
However, sustained HO-1 activity may also have negative consequences, including promotion of pro-oxidant iron release when ferritin induction is insufficient. [@peacock2023]
Genetic Associations
Polymorphisms in the HMOX1 gene have been associated with AD risk:
- (GT)n repeat polymorphisms: Affect HMOX1 transcriptional activity
- Promoter variants: Influence inducibility under stress
- Functional SNPs: May alter enzyme expression levels
Studies have reported inconsistent associations, likely due to population differences and gene-environment interactions. [@goetzl2020]
Therapeutic Implications
HO-1 represents a promising therapeutic target for AD:
- HO-1 inducers: Natural compounds (curcumin, sulforaphane) and pharmacological agents can upregulate HO-1 expression
- CO-releasing molecules: CO donors may provide neuroprotective effects without heme degradation
- Bilirubin analogs: Synthetic antioxidants based on biliverdin/bilirubin structures
- Gene therapy: AAV-mediated HO-1 delivery has shown promise in preclinical models
Role in Parkinson's Disease
HO-1 in PD Pathogenesis
[Parkinson's disease](/diseases/parkinsons-disease) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of [Lewy bodies](/mechanisms/alpha-synuclein-aggregation) containing [alpha-synuclein](/proteins/alpha-synuclein). HO-1 is profoundly upregulated in PD brains:
- Markedly elevated HO-1 in substantia nigra neurons
- Co-localization with Lewy bodies
- Association with disease severity
- Correlation with dopaminergic neuron loss
The pattern of HO-1 induction in PD suggests it plays a complex role in disease pathogenesis—initially protective but potentially contributing to iron dysregulation and progression with chronic activation. [@lin2007]
Mechanisms of HO-1 in PD
Alpha-synuclein Aggregation: HO-1 expression is induced by alpha-synuclein aggregates:
- Protein aggregates activate cellular stress pathways
- Oxidative stress from aggregates triggers HO-1 induction
- HO-1 may modulate alpha-synuclein aggregation and toxicity
Mitochondrial Dysfunction: PD involves complex I deficiency and mitochondrial dysfunction:
- HO-1 protects against mitochondrial oxidative damage
- CO preserves mitochondrial complex activity
- Bilirubin maintains mitochondrial membrane potential
Dopaminergic Neuron Vulnerability: Substantia nigra neurons are particularly susceptible:
- High iron content makes them vulnerable to oxidative stress
- HO-1 induction is particularly prominent in these neurons
- The balance between neuroprotection and iron release is critical
Iron Dysregulation: PD involves regional iron accumulation:
- HO-1 can release iron during heme catabolism
- Chronic HO-1 activity may contribute to iron load
- Ferritin induction may be insufficient to sequester released iron
Therapeutic Targeting in PD
HO-1-based therapies for PD include:
- Pharmacological inducers: Flavonoids, statins, and nutraceuticals
- Gene therapy: AAV-HO-1 delivery in preclinical models showed promise
- CO-releasing molecules: Low-dose CO may provide neuroprotection
- Combination approaches: HO-1 inducers with antioxidants or anti-inflammatory agents [@takahashi2017]
Role in Amyotrophic Lateral Sclerosis
HO-1 Expression in ALS
[Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) is a fatal neurodegenerative disorder affecting upper and lower motor neurons. HO-1 is upregulated in ALS:
- Increased expression in spinal cord motor neurons
- Localization to activated astrocytes and microglia
- Correlation with disease progression
- Detection in CSF as a potential biomarker
The induction of HO-1 in ALS represents a cellular stress response to motor neuron injury, protein aggregation, and neuroinflammation. [@kikuchi2022]
Mechanisms
Motor Neuron Vulnerability: Motor neurons exhibit specific vulnerabilities:
- High metabolic demand makes them susceptible to oxidative stress
- Protein aggregation triggers cellular stress responses
- HO-1 induction reflects attempts at neuroprotection
Glial Contributions: Astrocytes and microglia contribute to disease progression:
- Dysregulated neuroinflammation in ALS
- Astrocytic HO-1 may influence motor neuron survival
- Microglial HO-1 modulates neuroinflammation
Therapeutic Potential: Strategies to modulate HO-1 in ALS:
- Enhancement of beneficial HO-1 effects
- Prevention of maladaptive chronic activation
- Combination with other neuroprotective approaches
Role in Other Neurodegenerative Conditions
Stroke and Cerebral Ischemia
HO-1 is rapidly induced following cerebral ischemia-reperfusion injury:
- Protective effects in animal models of stroke
- CO-mediated vasodilation improves cerebral blood flow
- Anti-inflammatory actions reduce post-ischemic damage
- HO-1 gene therapy shows promise in preclinical studies [@chang2021]
Traumatic Brain Injury
Following [traumatic brain injury](/diseases/traumatic-brain-injury), HO-1 is induced as part of the injury response:
- Dual roles: initial protection versus chronic dysregulation
- Therapeutic window for HO-1 modulation
- Potential as a biomarker for injury severity [@wu2021]
Huntington's Disease
HO-1 expression is altered in [Huntington's disease](/diseases/huntingtons-disease):
- Upregulation in affected brain regions
- Relationship to mutant huntingtin toxicity
- Potential therapeutic target
Multiple Sclerosis and Demyelination
In demyelinating diseases, HO-1 is involved in:
- Oligodendrocyte protection
- Myelin repair processes
- Modulation of neuroinflammation
Ferroptosis and HO-1
Recent research has revealed important connections between HO-1 and [ferroptosis](/mechanisms/ferroptosis), a form of regulated cell death characterized by iron-dependent lipid peroxidation:
HO-1 as a Double-Edged Sword:
- Acute HO-1 induction can prevent ferroptosis by reducing labile iron and producing antioxidant biliverdin
- Chronic HO-1 activation can promote ferroptosis through iron release
- The timing and context of HO-1 activation determines its effects
Therapeutic Implications:
- Short-term HO-1 activation may be protective
- Iron chelation combined with HO-1 modulation
- Targeting the balance between protection and iron release [@xinhua2022]
Therapeutic Targeting Strategies
Pharmacological HO-1 Inducers
Several classes of compounds can upregulate HO-1 expression:
Natural Products:
- Curcumin: Strong HO-1 inducer via Nrf2 activation
- Sulforaphane: Broccoli-derived Nrf2 activator
- Resveratrol: Sirt1-mediated HO-1 upregulation
- Flavonoids: Wide range of HO-1 inducing activity [@chung2018]
Pharmacological Agents:
- Statins: HMG-CoA reductase inhibitors with HO-1 inducing properties
- Dimethyl fumarate: Approved for MS, activates Nrf2-HO-1 pathway
- Aspirin: Low-dose induces HO-1 in endothelial cells
CO-Releasing Molecules (CORMs)
CO-releasing molecules provide the beneficial effects of HO-1 activity without heme degradation:
- Metal-carbonyl based CORMs
- Light-activated CORMs
- Enzyme-triggered CO release
CO mediates:
- Anti-inflammatory signaling
- Anti-apoptotic effects
- Vasodilation
- Mitochondrial protection [@yoshikawa2020]
Gene Therapy Approaches
Viral vector-mediated HO-1 delivery:
- AAV-based gene therapy shows promise in preclinical models
- Targeted delivery to affected brain regions
- Controlled expression systems
- Combination with other therapeutic genes
Challenges and Considerations
Biphasic Nature of HO-1: The effects of HO-1 are context-dependent:
- Acute induction: Protective
- Chronic dysregulation: Potentially harmful
- Iron release vs. antioxidant protection balance
Cell-Type Specific Effects: HO-1 in different cell types may have distinct effects:
- Neuronal vs. astrocytic vs. microglial HO-1
- Therapeutic targeting must consider cell specificity
Systemic vs. CNS Effects: Peripheral HO-1 induction may have indirect CNS effects:
- Peripheral anti-inflammatory actions
- Modulation of gut-brain axis
- Systemic iron metabolism
Biomarker Potential: HO-1 has potential as:
- Disease progression biomarker
- Therapeutic response indicator
- Diagnostic tool in certain conditions [@caldi2022]
Key Publications and Clinical Evidence
[Schipper HM et al., Heme oxygenase-1 in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30658837/)
[Piantadosi CA et al., Heme oxygenase-1 and brain injury (2018)](https://pubmed.ncbi.nlm.nih.gov/29558546/)
[Song W et al., Heme oxygenase-1 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32280094/)
[Takahashi T et al., Heme oxygenase-1 gene therapy for Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28211946/)
[Dorazio JL et al., HO-1 upregulation in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34063289/)
[Kikuchi A et al., Heme oxygenase-1 in ALS pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35131726/)
[Chen J et al., Mitochondrial HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37164901/)
[Chang CF et al., HO-1 mediates neuroprotection in stroke (2021)](https://pubmed.ncbi.nlm.nih.gov/33539221/)
[Alam J et al., Nrf2-HO-1 pathway in cellular stress response (2022)](https://pubmed.ncbi.nlm.nih.gov/35617892/)
[Goetzl EJ et al., HO-1 polymorphisms and Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32937192/)
[Lin TK et al., Heme oxygenase-1 and Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17880941/)
[Chung JY et al., HO-1 induction by flavonoids in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29529512/)
[Nath KA et al., Heme oxygenase-2 and the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30600442/)
[Wu L et al., HO-1 in traumatic brain injury (2021)](https://pubmed.ncbi.nlm.nih.gov/33720856/)
[Caldi M et al., HO-1 targeting for neurotherapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35081745/)
[Kim DH et al., Iron metabolism and HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37178923/)
[Peacock L et al., Astrocyte HO-1 in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165012/)See Also
- [Proteins](/proteins/)
- [Oxidative Stress Proteins](/proteins/oxidative-stress-proteins/)
- [Heme Metabolism](/mechanisms/heme-metabolism/)
- [Neuroinflammation](/mechanisms/microglia-neuroinflammation/)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Ferroptosis](/mechanisms/ferroptosis/)
- [Nrf2 Pathway](/mechanisms/nrf2-antioxidant-pathway/)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction/)
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [Tau Protein](/proteins/tau)
External Links
- [UniProt P09601](https://www.uniprot.org/uniprot/P09601)
- [NCBI Gene HMOX1](https://www.ncbi.nlm.nih.gov/gene/3162)
- [Ensembl: ENSG00000123457](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123457)
- [GeneCards HMOX1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HMOX1)
- [OMIM 141630](https://omim.org/entry/141630)
References
[Schipper HM et al, Heme oxygenase-1 in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30658837/)
[Piantadosi CA et al, Heme oxygenase-1 and brain injury (2018)](https://pubmed.ncbi.nlm.nih.gov/29558546/)
[Song W et al, Heme oxygenase-1 in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32280094/)
[Takahashi T et al, Heme oxygenase-1 gene therapy for Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28211946/)
[Barsoum SB et al, Heme oxygenase-1 and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30658838/)
[Dorazio JL et al, HO-1 upregulation in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34063289/)
[Kikuchi A et al, Heme oxygenase-1 in ALS pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35131726/)
[Chen J et al, Mitochondrial HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37164901/)
[Chang CF et al, HO-1 mediates neuroprotection in stroke (2021)](https://pubmed.ncbi.nlm.nih.gov/33539221/)
[Yoshikawa M et al, Carbon monoxide signaling in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32205020/)
[Alam J et al, Nrf2-HO-1 pathway in cellular stress response (2022)](https://pubmed.ncbi.nlm.nih.gov/35617892/)
[Goetzl EJ et al, HO-1 polymorphisms and Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32937192/)
[Lin TK et al, Heme oxygenase-1 and Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17880941/)
[Chung JY et al, HO-1 induction by flavonoids in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29529512/)
[Nath KA et al, Heme oxygenase-2 and the brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30600442/)
[Wu L et al, HO-1 in traumatic brain injury (2021)](https://pubmed.ncbi.nlm.nih.gov/33720856/)
[Caldi M et al, HO-1 targeting for neurotherapeutics (2022)](https://pubmed.ncbi.nlm.nih.gov/35081745/)
[Kim DH et al, Iron metabolism and HO-1 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37178923/)
[Schipper HM et al, Heme oxygenase: a novel target for oxidative brain injury (2000)](https://pubmed.ncbi.nlm.nih.gov/10677139/)
[Xin Q et al, HO-1 and ferroptosis in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35575291/)
[Peacock L et al, Astrocyte HO-1 in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165012/)